Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bradley Boyd

Orthopaedic Surgery Fairfax, VA Doctor of Osteopathy

NPI 1134384720 CMS profile 1280841

3620 Jospeh Siewick Dr Ste 201, Fair Oaks Orthopaedic Associates, Fairfax, VA 22033

Open in the dashboard

General payments

$540,145

646 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bradley Boyd of Fairfax, VA is reported in the CMS Open Payments database as having received $540,145 across 646 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $94,486 84
2024 General $75,717 63
2023 General $65,683 92
2022 General $67,480 101
2021 General $94,851 130
2020 General $68,823 73
2019 General $73,104 103

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bradley Boyd
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Bradley Boyd were reported at $94,486. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Bradley Boyd Orthopaedic Surgery median Middle half National median
2019 $73,104 $644 $140–$2,844 $163
2020 $68,823 $312 $75–$1,860 $114
2021 $94,851 $520 $117–$2,495 $132
2022 $67,480 $598 $128–$2,731 $149
2023 $65,683 $461 $128–$2,264 $160
2024 $75,717 $497 $134–$2,475 $164
2025 $94,486 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $515,769 582 payments
  2. Flexion Therapeutics, Inc. $23,415 31 payments
  3. Amgen Inc. $147 2 payments
  4. Avanos Medical $140 1 payment
  5. DePuy Synthes Sales Inc. $121 1 payment
  6. Pacira Pharmaceuticals Incorporated $69 3 payments
  7. Ethicon US, LLC $63 2 payments
  8. Horizon Therapeutics plc $58 4 payments
  9. Davol Inc. $54 2 payments
  10. Fidia Pharma USA Inc. $45 3 payments
  11. Other $264 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $435,175 134 payments
  2. Travel and Lodging $69,321 228 payments
  3. Honoraria $20,494 11 payments
  4. Food and Beverage $15,155 273 payments
Products named General payments · program years 2019–2025
  1. MAKO Knees, Hips $383,365 394 payments
  2. MAKO Knees, Hips $119,242 119 payments
  3. Zilretta $23,415 31 payments
  4. INSIGNIA $16,653 5 payments
  5. AEQUALIS $15,950 2 payments
  6. ACCOLADE $12,849 7 payments
  7. TRIDENT $6,000 1 payment
  8. RESTORATION $6,000 1 payment
  9. TRIATHLON $3,488 10 payments
  10. ASCENTIAL ACP 1 $2,600 1 payment
  11. Other $7,332 85 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

1,302

Median for Orthopedic Surgery: 203

Drug cost

$13,291

Median for Orthopedic Surgery: $1,433

Branded share of claims

10.7%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 114 $5,050
Mupirocin Generic 289 $2,229
Cefuroxime Cefuroxime Axetil Brand 94 $1,393
Gabapentin Generic 160 $1,076
Oxycodone Hcl Generic 159 $727
Tramadol Hcl Generic 238 $643
Dexamethasone Generic 72 $509
Tizanidine Hcl Generic 17 $382
Diclofenac Sodium Generic 25 $334
Cephalexin Generic 19 $255

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$589,768

Of which drugs: $38,903

Medicare patients

947

Average age 75

Services billed

9,289

635 women, 312 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Chronic kidney disease 24%
Ischemic heart disease 23%
Osteoporosis 22%
Diabetes 20%
Depression 16%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, triluron, for intra-articular injection, 1 mg J7332 Office 87 4,800 $38,266
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 126 850 $618

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KRYSTEXXA
  • Amgen Inc. $28
$28 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

646 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record